When it comes to approving new medical treatments, the Food and Drug Administration is balancing the need for patient safety against the urgency of making important new treatments available as quickly as possible.
Some argue the FDA sets the bar too high, requiring a process that takes too much time and money to carry out. They say that can leave patients waiting longer than necessary for promising treatments or lead to drugs not being developed at all. But others counter that letting drugs on the market before it's known whether they truly help or hurt patients is a serious risk. They argue that the FDA actually has a high rate of approving new drugs — and that in critical cases, that process can be accelerated. A team of experts recently faced off two against two for an Intelligence Squared U.S. debate on the motion "The FDA's Caution Is Hazardous to Our Health." Before the debate, the audience voted 24 percent in favor of the motion, with 32 percent against and 44 percent undecided. After the debate, 53 percent agreed "The FDA's Caution Is Hazardous to Our Health," while only 38 percent disagreed — making the side arguing in favor of the motion the winners of the debate.
| 
窥视卡
雷达卡
发表于 2015-5-12 11:07:20
提升卡
置顶卡
沉默卡
喧嚣卡
变色卡
千斤顶
显身卡
发表于 2015-5-13 07:55:22
